What do systematic reviews say?

4 questions · 8 findings · 1 reviews · related questions CL0289

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 25%Very low 0 · 0%Low 3 · 37.5%Moderate 2 · 25%High 1 · 12.5%

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash

Oral mucositis (severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone

Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (severe) compared with chlorhexidine mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 0.01 [0.00, 0.19]
1 study · 90 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs Chlorhexidine mouthwash

Oral mucositis (moderate to severe) · Children with acute lymphoblastic leukaemia receiving chemotherapy alone

Keratinocyte growth factor (KGF), intravenous led to lower oral mucositis (moderate to severe) compared with chlorhexidine mouthwash; GRADE not reported.

1 finding from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Children
RR 0.12 [0.05, 0.28]
1 study · 90 participants
GRADE not reported

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Oral mucositis (severe) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (severe) compared with placebo (low certainty).

3 findings from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemotherapy alone for mixed cancers
RR 0.30 [0.14, 0.65]
3 studies · 263 participants
Low
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 0.85 [0.65, 1.11]
6 studies · 852 participants
Low
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck with cisplatin/fluorouracil
RR 0.79 [0.69, 0.90]
3 studies · 471 participants
High

Keratinocyte growth factor (KGF; palifermin or repifermin), intravenous vs placebo

Oral mucositis (moderate to severe) · Adults with cancer receiving treatment

Keratinocyte growth factor (KGF; palifermin or repifermin),… may leads to lower oral mucositis (moderate to severe) compared with placebo (low certainty).

3 findings from 1 review

Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
BMT/SCT after conditioning for haematological cancers
RR 0.89 [0.80, 0.99]
6 studies · 852 participants
Low
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
RT to head and neck with cisplatin/fluorouracil
RR 0.91 [0.83, 1.00]
3 studies · 471 participants
Moderate
Interventions for preventing oral mucositis in patients with cancer receiving treatment: cytokines and growth factors 2017 · Cochrane All outcomes
Chemotherapy alone for mixed cancers
RR 0.56 [0.45, 0.70]
4 studies · 344 participants
Moderate